✦ LIBER ✦

Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?

✍ Scribed by Mathis Grossmann; Jeffrey D. Zajac

Book ID: 108704803
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 57 KB
Volume: 74
Category: Article
ISSN: 0300-0664
DOI: 10.1111/j.1365-2265.2010.03939.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Increase in visceral and subcutaneous ab

Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy

✍ E. J. Hamilton; E. Gianatti; B. J. Strauss; J. Wentworth; D. Lim-Joon; D. Bolton 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Review of major adverse effects of andro

Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer

✍ Lockwood G. Taylor; Steven E. Canfield; Xianglin L. Du 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 1 views

Long-term side effects of androgen depri

Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review

✍ Shabbir M.H. Alibhai; Sven Gogov; Zishan Allibhai 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 197 KB

The effect of androgen deprivation thera

The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis

✍ Farhana Haseen; Liam J. Murray; Chris R. Cardwell; Joe M. O’Sullivan; Marie M. C 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 280 KB

Pretreatment prostate-specific antigen v

Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy

✍ David Palma; Scott Tyldesley; Tom Pickles; for the Prostate Cohort Outcomes Init 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

## Abstract ## BACKGROUND In men with prostate cancer, pretreatment prostate‐specific antigen (PSA) velocity (PSAV) has been demonstrated as a predictor of biochemical and survival outcomes in patients undergoing radical prostatectomy (RP). The utility of pretreatment PSAV in predicting outcomes a

Does androgen-deprivation therapy accele

Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? : A conceptual review

✍ Kathryn Bylow; Supriya G. Mohile; Walter M. Stadler; William Dale 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 1 views

## Abstract The majority of men with prostate cancer are aged ≥65 years. Men, as they age, are more likely to suffer from impaired physical function. The standard treatment for recurrent prostate cancer is androgen‐deprivation therapy (ADT). Well‐established toxicities from ADT include lean weight